Positron Emission Tomography (PET) Radiotracer Market Report 2026

Positron Emission Tomography (PET) Radiotracer Market Overview

• Positron Emission Tomography (PET) Radiotracer market size has reached to $2.54 billion in 2025 • Expected to grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Increasing Prevalence Of Infectious Diseases Is Driving The Growth Of The Positron Emission Tomography (PET) Radiotracer Market • Market Trend: Advancements In Positron Emission Tomography (PET) Radiotracers for Enhanced Cancer Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Positron Emission Tomography (PET) Radiotracer Market?

A positron emission tomography (PET) radiotracer refers to a radioactive substance used in positron emission tomography (PET) imaging. A PET radiotracer is utilized by injecting a patient with a radioactive substance that binds to specific biological targets, allowing the PET scanner to visualize metabolic activity and diagnose conditions such as cancer or neurological disorders. The main types of positron emission tomography (PET) radiotracers are F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), and others. F-18 (Fluorodeoxyglucose 18) radiotracers refer to a radioactive glucose analog used in positron emission tomography (PET) imaging to assess metabolic activity in tissues, particularly for detecting cancer. These radiotracers have been applied in various medical fields, including cancer, heart disease, gastrointestinal disorders, endocrine issues, neurological disorders, and others. They are utilized by end users such as hospitals, diagnostic centers, and others.

What Is The Positron Emission Tomography (PET) Radiotracer Market Growth Forecast?

The positron emission tomography (pet) radiotracer market size is expected to see strong growth in the next few years. It will grow to $3.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for precision diagnostics, rising investments in radiopharmaceutical R&D, expansion of theranostics applications, growing adoption of pet imaging in neurology and cardiology, increasing regulatory approvals for new tracers. Major trends in the forecast period include increasing development of target-specific radiotracers, rising adoption of pet imaging in oncology diagnostics, growing use of novel isotopes beyond fdg, expansion of personalized nuclear medicine applications, enhanced focus on short-half-life radiotracer production.

Global Positron Emission Tomography (PET) Radiotracer Market Segmentation

1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types 2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications 3) By End-User: Hospitals, Diagnostic Centers, Other End-Users Subsegments: 1) By F-18 (Fluorodeoxyglucose 18): F-18 FDG (Fluorodeoxyglucose), F-18 Fluoroethyltyrosine (FET), F-18 Florbetapir (Amyloid PET Imaging) 2) By Ga-68 (Fibroblast Activation Protein Inhibitor): Ga-68 Dotatate (Neuroendocrine Tumor Imaging), Ga-68 PSMA (Prostate-Specific Membrane Antigen Imaging), Ga-68 FAPI (Fibroblast Activation Protein Inhibitor Imaging) 3) By Other Radiotracer Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Rb-82 (Rubidium-82), I-124 (Iodine-124)

What Is The Driver Of The Positron Emission Tomography (PET) Radiotracer Market?

The increasing prevalence of infectious diseases is expected to propel the growth of the positron emission tomography (PET) radiotracer market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. The rising prevalence of infectious diseases is due to climate change, urbanization, globalization, antibiotic resistance, and changes in human behavior, which all facilitate the spread of pathogens. Positron emission tomography (PET) radiotracers help infectious diseases by visualizing metabolic activity and inflammation, enabling detection of infection, assessment of treatment response, and differentiation between infectious and non-infectious conditions for better patient outcomes. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Therefore, the increasing prevalence of infectious diseases is driving the growth of the positron emission tomography (PET) radiotracer industry.

Key Players In The Global Positron Emission Tomography (PET) Radiotracer Market

Major companies operating in the positron emission tomography (pet) radiotracer market are Cardinal Health Inc., GE Healthcare Technologies Inc., Bracco Imaging S.p.A., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., ImaginAb Inc., Radiomedix Inc., Curium Pharma, Blue Earth Diagnostics Ltd., Eckert & Ziegler Radiopharma GmbH, Advanced Accelerator Applications (Novartis), Telix Pharmaceuticals Limited, PETNET Solutions Inc., Piramal Imaging

Global Positron Emission Tomography (PET) Radiotracer Market Trends and Insights

Major companies operating in the positron emission tomography (PET) radiotracer market are focusing on developing advanced diagnostic solutions, such as positron emission tomography imaging agents to enhance cancer detection and improve patient outcomes. A positron emission tomography (PET) imaging agent refers to a radioactive substance used to visualize and measure biological processes in the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada as a prostate cancer imaging agent designed to detect metastatic prostate cancer. This tool is valuable for physicians in identifying metastatic disease and aiding in patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, as well as in those with suspected recurrence indicated by elevated serum prostate-specific antigen (PSA) levels.

What Are Latest Mergers And Acquisitions In The Positron Emission Tomography (PET) Radiotracer Market?

In February 2023, Lantheus Holdings Inc., a US-based developer of diagnostic products, acquired Cerveau Technologies for an undisclosed amount. Through this acquisition, Lantheus Holdings aims to enhance its imaging pipeline, particularly for Alzheimer's disease diagnostics, by incorporating Cerveau's MK-6240, a second-generation PET imaging agent that targets tau tangles in the brain. Cerveau Technologies Inc. is a US-based provider of information and technology and involves positron emission tomography (PET) radiotracers.

Regional Outlook

North America was the largest region in the positron emission tomography (PET) radiotracer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Positron Emission Tomography (PET) Radiotracer Market?

The positron emission tomography (PET) radiotracer market consists of sales of FDG (fluorodeoxyglucose), f-dopa (fluorodopa), C-11 methionine, C-11 methionine, F-18 naf (sodium fluoride), and C-11 choline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.